X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Merck India: Restructuring drives growth - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • Dec 30, 2003

    Merck India: Restructuring drives growth

    Merck India is a 51% subsidiary of Merck KgaA, Germany. The company derives almost 60% of its revenues from its pharmaceutical business and the balance from chemicals. The company’s pharmaceutical business comprises mainly of vitamins, cardio-vascular drugs, and cough and cold preparation. The chemical business on the other hand, comprises of analytics, reagents, scientific laboratory products and pigments.

    In the pharma business, delay in the implementation of liberalised pricing legislation and reduction in the prices of certain drugs (like Neurobion Forte tablets) by the government resulted in the company registering stagnant growth in pharma sales in FY03. In the chemicals business, during FY03, while the analytics and reagents division and pigments division grew by 17% and 52% respectively, scientific laboratory products division registered a 29% drop. The performance of the scientific laboratory products division was affected due to competition from Europe and China. Resultantly, the company, as a whole, had reported a marginal 2% growth in net sales and an 11% drop in net profits during FY03.

    Results at a glance...
    (Rs m) 3QFY03 3QFY04 Change 9mFY03 9mFY04 Change
    Net Sales 894 979 9.5% 2,644 2,712 2.6%
    Other Income 18 39 119.1% 54 80 48.9%
    Expenditure 722 728 0.7% 2,191 2,128 -2.9%
    Operating Profit (EBDIT) 171 251 46.5% 453 584 29.0%
    Operating Profit Margin (%) 19.2% 25.6%   17.1% 21.5%  
    Interest 1 1 -11.0% 2 8 242.5%
    Depreciation 25 22 -10.6% 73 70 -3.5%
    Profit before Tax 163 267 63.5% 431 586 35.9%
    Tax 55 94 71.6% 138 205 48.2%
    Profit after Tax/(Loss) 108 173 59.4% 293 381 30.0%
    Net profit margin (%) 12.1% 17.7%   11.1% 14.0%  
    No. of Shares 17 17   17 17  
    Diluted Earnings per share* 25.7 41.0   23.2 30.1  
    P/E Ratio   10.7     14.6  
    (* annualised)            

    The stagnancy in topline growth continued during 9mFY04 with Merck India reporting a meager 3% growth. The topline growth was due to a 5% growth in the chemicals segment. The pharma business, however, registered a marginal 1% growth. On the operations front, various cost cutting measures undertaken by the company has helped it record an impressive 440 basis point improvement in operating profit margins. The company has discontinued manufacturing activities at its Taloja factory, which has helped bring down costs considerably. This apart, in 2003, 281 employees have opted for Merck’s voluntary retirement scheme, resulting in a drop in the staff cost. However, the raw material cost saw a sharp increase due to an additional charge made by the company for writing down the value of its inventory.

    Expenditure as a percentage of net sales...
    (Rs m) 3QFY03 3QFY04 9mFY03 9mFY04
    Raw material 22.9% 27.8% 22.7% 30.3%
    Purchase of traded goods 26.3% 19.9% 25.7% 18.9%
    Staff cost 11.9% 9.4% 14.2% 11.9%
    Other expenditure 19.7% 17.3% 20.2% 17.4%

    An improvement in operating profits coupled with an increase in other income has helped the company register an impressive 30% growth in bottomline.

    At Rs 440, Merck India is trading at a P/E multiple of 15x its 9mFY04 earnings. Competition from generics and small-scale manufacturers is eating into the company’s market share in the pharma and laboratory reagents division. Meanwhile, competition form China continues to adversely affect the company’s performance in the pigments division. This apart, the general performance of the pharma sector is also being affected by the delay in the implementation of DPCO 2002. To this extent, investors need to exercise caution while investing in this stock.

     

     

    Equitymaster requests your view! Post a comment on "Merck India: Restructuring drives growth". Click here!

      
     

    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

    May 30, 2017

    US markets decline while other geographies grow in the quarter.

    More Views on News

    Most Popular

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

    Aug 10, 2017

    Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    Bitcoin Continues Stellar Rise(Chart Of The Day)

    Aug 10, 2017

    Bitcoin hits an all-time high, is there more upside left?

    5 Steps To Become Financially Independent(Outside View)

    Aug 16, 2017

    Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    MERCK LTD SHARE PRICE


    Aug 22, 2017 (Close)

    TRACK MERCK LTD

    • Track your investment in MERCK LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks

    MERCK LTD 8-QTR ANALYSIS

    Detailed Quarterly Results With Charts

    COMPARE MERCK LTD WITH

    MARKET STATS